# 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

> **NCT03490032** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advanced Accelerator Applications** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** [68Ga]-PSMA-R2

## Key facts

- **NCT ID:** NCT03490032
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-09-13
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490032, "68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03490032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*